Cargando…

Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects

To evaluate the safety and efficacy of combining Endostar antiangiogenic therapy with neoadjuvant chemotherapy for the treatment of stage IIIA (N2) NSCLC, we conducted a randomized, controlled, open-label clinical study of 30 NSCLC patients. Patients were randomly assigned to the test or control gro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Xiaoliang, Su, Yanjun, You, Jian, Gong, Liqun, Zhang, Zhenfa, Wang, Meng, Zhao, Zhenqing, Zhang, Zhen, Li, Xiaolin, Wang, Changli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308751/ https://www.ncbi.nlm.nih.gov/pubmed/27566586 http://dx.doi.org/10.18632/oncotarget.11547

Ejemplares similares

Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center
por: Zhu, Jianquan, et al.
Publicado: (2021)

The Function of SARI in Modulating Epithelial-Mesenchymal Transition and Lung Adenocarcinoma Metastasis
por: Wang, Changli, et al.
Publicado: (2012)

Survival analysis of patients with non-small cell lung cancer who underwent surgical resection following 4 lung cancer resection guidelines
por: Yue, Dongsheng, et al.
Publicado: (2014)

Prognostic value of number of negative lymph node in patients with stage II and IIIa non-small cell lung cancer
por: Wang, Shengguang, et al.
Publicado: (2017)

Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)
por: Hui, Zhenzhen, et al.
Publicado: (2022)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Real-World Effectiveness and Prognostic Factors Analysis of Stages I–III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy
por: Liu, Zuo, et al.
Publicado: (2021)

Reappraisal of the role of postoperative radiation therapy in patients with pIIIa-N2 non-small cell lung cancer: A propensity score matching analysis
por: Cao, Qinchen, et al.
Publicado: (2015)

The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non–Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors
por: Sun, Xiaoyan, et al.
Publicado: (2022)

Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report
por: Wang, Hongming, et al.
Publicado: (2023)

Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study
por: Huang, Zhangfeng, et al.
Publicado: (2021)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
por: Li, Xin, et al.
Publicado: (2022)

Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Chen, Dong, et al.
Publicado: (2021)

Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial
por: Lei, Jie, et al.
Publicado: (2023)

lncRNA-u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling
por: Wei, Wei, et al.
Publicado: (2019)

Efficacy and outcome analysis: Combination of Endostar and chemotherapy as a neoadjuvant treatment of stage IIIA/IIIB squamous cell lung cancer
por: Cao, Feiyi, et al.
Publicado: (2023)

Prognostic significance of 4R lymph node dissection in patients with right primary non-small cell lung cancer
por: Zhou, Di, et al.
Publicado: (2022)

The prognostic value of the preoperative albumin to alkaline phosphatase ratio in patients with non‐small cell lung cancer after surgery
por: Zhang, Lianmin, et al.
Publicado: (2019)

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy
por: Ebos, John ML, et al.
Publicado: (2014)

Clinical analysis of 78 pulmonary sarcomatoid carcinomas with surgical treatment
por: Gong, Ting, et al.
Publicado: (2022)

Increased Malignant Microcalcifications after Neoadjuvant Chemotherapy in Advanced Breast Cancer
por: Shin, Gi Won, et al.
Publicado: (2016)

Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis
por: Ge, Pu, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer
por: Zhu, Xudong, et al.
Publicado: (2019)

Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I–IIIA small-cell lung cancer: a retrospective single-arm clinical trial
por: Liu, Jiacong, et al.
Publicado: (2022)

MicroRNA‐130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt/β‐catenin pathway
por: Zhang, Qiang, et al.
Publicado: (2018)

Identification of a DNA damage repair gene‐related signature for lung squamous cell carcinoma prognosis
por: Jia, Bin, et al.
Publicado: (2022)

Abstract: Neoadjuvant Chemotherapy Is Not Associated with Increased Risk of Complications in Immediate Breast Reconstruction
por: Karam, Andrew, et al.
Publicado: (2018)

Transcobalamin I: a novel prognostic biomarker of neoadjuvant chemotherapy in locally advanced hypopharyngeal squamous cell cancers
por: Wang, Ying, et al.
Publicado: (2018)

PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127(+) and KLRG1(+) CD8 T cells
por: Hui, Zhenzhen, et al.
Publicado: (2023)

Increased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy
por: Liu, Jiawei, et al.
Publicado: (2019)

Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients
por: Yue, Dongsheng, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade
por: Luo, Hao, et al.
Publicado: (2022)

Levosulpiride Increases the Levels of Prolactin and Antiangiogenic Vasoinhibin in the Vitreous of Patients with Proliferative Diabetic Retinopathy
por: Nuñez-Amaro, Carlos D., et al.
Publicado: (2020)

Efficacy of Crizotinib Combined with Chemotherapy in Treating Advanced Non-Small-Cell Lung Cancer and Effect on Patients' Quality of Life and Adverse Reaction Rate
por: Ma, Zaiqi, et al.
Publicado: (2022)

Increased Alveolar Heparan Sulphate and Reduced Pulmonary Surfactant Amount and Function in the Mucopolysaccharidosis IIIA Mouse
por: Paget, Tamara L., et al.
Publicado: (2021)

Does neoadjuvant chemotherapy increase breast conservation in operable breast cancer: an Egyptian experience
por: Abdel-Bary, N, et al.
Publicado: (2009)

Downregulation of LINC00665 suppresses the progression of lung adenocarcinoma via regulating miR-181c-5p/ZIC2 axis
por: Wei, Wei, et al.
Publicado: (2021)

Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
por: Sun, Xiaoyan, et al.
Publicado: (2022)

Antiangiogenic therapy using endostatin increases the number of ALDH+ lung cancer stem cells by generating intratumor hypoxia
por: Yu, Yang, et al.
Publicado: (2016)

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
por: Provencio, Mariano, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ka15df2atd6turro67es3amllq